FDA Plans to Exclude Three Substances From 503B List

The FDA is proposing to exclude three substances from its 503B Bulks List of substances for outsourcing facilities to use in compounding drugs — including one that’s the subject of an Endo lawsuit against the agency.
Source: Drug Industry Daily